Markets › LSE › 0I1B.L

Enovis Corporation

LSE:0I1B.LHealthcare

——At close · Market cap — · Next earnings Wed 4 Nov

USD billions	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025	YoY
Revenue	3.1	1.4	1.6	1.7	2.1	2.2	+6.7%
Cost of revenue	1.9	0.8	0.8	0.7	1.1	1.1	+0.1%
Gross profit	1.1	0.7	0.7	1.0	1.0	1.2	+13.6%
Research & development	0.1	0.0	0.1	0.1	0.1	0.1	+31.8%
Selling, general & administrative	0.8	0.6	0.7	0.8	0.9	1.0	+6.2%
Selling & marketing	0.0	0.0	0.0	0.0	0.0	0.0	—
Operating expenses	0.9	0.7	0.8	1.1	1.0	1.2	+12.9%
Operating income	0.2	(0.0)	(0.0)	(0.1)	(0.0)	0.0	+180.8%
Interest expense	0.1	0.0	0.0	0.0	0.1	0.1	+45.1%
Interest income	0.0	0.0	0.0	0.0	0.0	0.0	+8050.0%
Other income / expense	(0.2)	(0.1)	0.0	(0.0)	(0.8)	(1.2)	−41.9%
Pre-tax income	0.1	(0.1)	(0.0)	(0.1)	(0.8)	(1.2)	−40.9%
Income tax	(0.0)	(0.0)	0.0	(0.0)	0.0	0.0	+396.3%
Net income	0.1	0.1	(0.0)	(0.0)	(0.8)	(1.2)	−43.3%
Discontinued operations	(0.0)	0.2	0.0	0.0	0.0	0.0	−100.0%
Other net income adjustments	0.0	0.0	0.0	0.0	0.0	0.0	—
EPS, basic (per share)	1.13	1.22	(0.28)	(0.90)	(14.93)	(20.72)	−38.8%
EPS, diluted (per share)	1.11	1.22	(0.28)	(0.90)	(14.93)	(20.72)	−38.8%
EBITDA	0.4	0.1	0.2	0.2	(0.5)	0.3	+161.9%
Depreciation & amortization	0.2	0.2	0.2	0.2	0.3	0.3	+3.3%
Weighted average shares (shares)	45,588,707	51,141,261	54,065,420	54,494,823	55,280,647	57,068,626	+3.2%
Weighted average diluted shares (shares)	46,303,475	51,141,261	54,065,420	54,494,823	55,280,647	57,068,626	+3.2%
Gross margin	37.0%	46.1%	47.2%	58.2%	48.7%	51.9%	+3.2 pts
Operating margin	7.7%	−1.6%	−1.7%	−3.8%	−0.2%	0.1%	+0.3 pts
Net margin	1.7%	4.4%	−1.0%	−1.9%	−39.2%	−52.6%	−13.4 pts

USD billionsUpdated Tue 31 Mar ·

ⓘ

Amounts are shown in the stated units; per-share amounts and shares are unscaled. Negative amounts are in brackets.